Disparities of Trastuzumab Use in Resource‐Limited or Resource‐Abundant Regions and Its Survival Benefit on HER2 Positive Breast Cancer: A Real‐World Study from China

BACKGROUND. Trastuzumab is a key component of therapy for human epidermal growth receptor 2 (HER2) positive breast cancer. Because real‐world data are lacking, the present research was conducted to evaluate the actual use of and the effectiveness of trastuzumab in the real world in China. METHODS. I...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Oncologist
Main Authors: Li, Jianbin, Wang, Shusen, Wang, Yongsheng, Wang, Xiaojia, Wang, Haibo, Feng, Jifeng, Zhang, Qingyuan, Sun, Tao, Ouyang, Quchang, Yin, Yongmei, Liu, Yinhua, Geng, Cuizhi, Yan, Min, Jiang, Zefei
Format: Artigo
Jezik:Inglês
Izdano: AlphaMed Press 2017
Teme:
Global Health and Cancer
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5679829/
https://ncbi.nlm.nih.gov/pubmed/28798274
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2017-0088
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki